1,25(OH),D, has been shown to promote cellular differentiation and inhibit proliferation. in vitro. of haematopoietic cells (Abe et al. 1981 : Bar et al. 1983 : Rigby et al. 1984 . cancer cells (Colston et al. 1981 : Frampton et al, 1983 , Brehier et al. 1988 ) and the epidermis (Hosomi et al. 1988 ). 1.25(OH),D, and its metabolites have also been shown to inhibit cell proliferation in human rectal mucosa (Thomas et al. 1992 ). In addition I,25(OH),D, has been shown to inhibit tumour-induced angiogenesis (Majewski et al, 1993) and to inhibit the invasive potential of human breast cancer cells in vitro (Hansen et al. 1994) . Recently. 1,25(OH),D, was also shown to induce apoptosis in human breast cancer and leukaemic cell lines (Elstner et al. 1995 : James et al. 1995 . The hormone mediates its action through the activation of the vitamin D receptor. which is a member of the superfamily of nuclear receptors (Mangelsdorf et al. 1995) . The receptor-ligand complex functions as a transcription factor and binds to DNA through interaction with vitamin D response elements. leading to either activation or suppression of target gene transcnption (Hanna and Norman. 1994: Carlberg. 1995) . Vitamin D receptor expression has also been positively correlated with survival in breast cancer (Berger et al. 1987) .
Laboratory studies have demonstrated that 1,25(OH),D, may be of value in the treatment of hyperproliferative disorders such as leukaemia. psoriasis. prostate cancer and breast cancer (Eisman et al. 1987 : Zhou et al. 1990 : Kragballe. 1992 SkoATonski et al, 1993) . However, such treatment has frequently resulted in the induction of hypercalcaemia at doses exceeding more than a few micrograms per day.
In an attempt to circumvent this, a number of analogues have been produced. mainly by minor structural modification of the sidechain at the C-17 position. in order to depress calcaemic activity while enhancing antiproliferative effects (Abe et al, 1987 : Ostrem et al. 1987 : Binderup et al. 1988 : Elstner et al. 1994 . One such compound. MC903. has been shown to be effective in the topical treatment of psonrasis (Kragballe et al. 1991 : Bagot et al. 1994 ) and has also been beneficial in stabilizing locally advanced and cutaneous metastatic breast cancer (Bower et al. 1991 ). An analogue with greater potential. EB 1089 (Figure 1 ). has been investigated and has been found to inhibit the growth of breast cancer cells in vitro and in vivo (Colston et al. 1992 : James et al. 1994 . These studies showed that EB 1089 administration failed to cause significant hypercalcaemia at doses that were capable of causing regression of mitrosomethylurea (NMU)-induced rat mammary tumours. At a dose of 0.5 jg kg-' body weight the compound inhibited tumour growth in the absence of hypercalcaemia. whereas the Compassionate treatment for up to 1 year was allowed and commenced at the end of the per protocol treatment. The same dose level was to be given as that used in the per protocol phase. but this could be reduced if hypercalcaemia had been recorded during the per protocol phase or developed during compassionate treatment. In patients who became hypercalcaemic. EB 1089 treatment was stopped and the serum calcium allowed to return to normal before treatment recommenced.
Calcium diet All patients were seen by the hospital dietitian and commenced a low-calcium diet (an estimated 500 mg day-') at the start of the British Jourmal of Cancer (1998) (1998) Phase I study of EB 1089 9 was carried out according to standard UICC criteria (Hayward et al, 1987 
Detemination of maximum toleated dose (MD)
The MTD was determined by the continual reassessment method (CRM).
Patients were entered sequentially and allocated to a dose level, determined by the observed toxicity in the previously teated patients, using an extension of the CRM (O'Quigley et al, 1990; Moller, 1995) . The method is based on a determination of an acceptable level of toxic response (x = 40%) and the assumption that the dose-response curve of the probability of experiencing a severe toxicity could be described by a family of monotone functions: f(x,a), depending on the dose, x, and a parameter, ca, monotonously in both x and a. For each new observation of toxicity or no toxicity in a patient teated at dose x, the curve will be re-estimated based on all the available observations by estimating the parameter, a, and the dose corresonding to the acceptable level of toxic response (MTD) will be calculated by: p(MTD) = f(MTD, a) = x, and given to the next patient
The family of dose-onse curves for the dose determination is f(z(x),a) = ((tanhz(x))) + l)2)a, where z(x) is a linear finction of x, nomalizing the interval so that f(z, 1) will take values in the interval (0.05, 0.70) for the range of dose levels considered. The prior distribution of a before any patient entered is: g(a) = EXP (-a 
Per prontoco treatm
Eleven patients received the single day's dosing followed by the 5-day repeated dosing period at dose levels of 0.15-0.6 gg m-2.
Twenty-five patients received only the 5-day repeated dosing at dose levels of 0.9-17 ig in-2. The different positive disease sites, as well as tumour sizes, were similarly distributed amongst the dose steps. Neither hypercalciuria nor hypercalcaemia was recorded with one day's dosing. Eleven patients became hypercalcaemic during the 5-day repeated dosing. Four of these patients had severe hypercalcaemia at doses of 0.45, 12.5 and 17 (two) jg m-2. The patient given 0.45 jg m-2 became severely hypercalcaemic after 3 days, coincidental with a dramatic deterioration in her condition, including a marked fall in serum albumin, leading to an increase in corrected serum calcium, and died shortly after from the underlying disease. Figure 2 shows the ratios of end of the 5-day repeated dosing period (day 6) to baseline (day 1) for the following parameters:
corrected serum calcium, 24 h urine calcium, serum PTH, serum creatinine against EB 1089 dose in jg m-2. P-values given are from linear regression on log ratio (day 6/day 1) by dose level (.ug mr2).
There is a significant effect of EB 1089 on urinary calcium (P = 0.0001), and on the cofrected serum calcium (P = 0.027), both increasing with dose. Tlere is also a highly sigifint inverse Phase I study of EB 1089 11 relationship with serum parathyroid hormone level (P = 0.0001) and the relationship between EB 1089 and serum creainine also achieved significance (P = 0.024).
Compasse _eament
Twenty-one patients received compassionate treatment for between 10 and 234 days (mean 90 ± 62 days) ( 
Estmate of MTD
The dose-response curve with respect to toxicity was estimated after the study was completed, based on the last 11 patients who received the 5-day repeated dosing at dose levels 7-17 jig mi-2. The (Vieth, 1990) .
It is encouraging that the expected decrease in calcaemic activity of EB 1089 relative to that of its parent compound,
(1,25(OH),D3), has translated into the clinical setting. Certainly the dose esfimated to be tolerable to patients (7 jig m-2, corresponding to around 0.2 jig kg-' in man) is similar to, or greater than, those shown to have anti-tumour tumour effects in animal models (Haq et al, 1993; Colston, 1994; DL Morris, personal communication The relationship between EB 1089 dose and serum creatnine seen with acute (5 day) doses is not explained. However, this funding is in accordance with odter trials involving calcitriol, alphacalcidol and other analogues. These studies report reversible increases m serum creatine, with other changes in measurements of renal function, such as creatinine cleaance, not being demonstrate (Tvedegaard et aL 1988; Bertoli et al, 1990 ). Creatinine clearance was not detrmined in our study. However, it is reassuring to note that when EB 1089 was given for prolonged periods during compassionate treatment there was no change in serum creanine.
We failed to observe any anti-tumour effects in our patients. However, all patients had received anti-cancer therapy previously and many of the breast cancer patients had been given more than three different therapeutic regimens in the past. It is reasonable to expect that the 'differentiation agents', such as EB 1089, are unlikely to have a measurable effect in this setting. Responses to these agents may be more likely in the earlier stages of disease or in patients with minial disease.
Recent research on new synthetic vitamin D analogues clearly shows the possibility of developing derivatives that separate potent modulatory effects on cell growth and differentiation and effects on calcium homeostasis, and has established an exciting potential for these compounds as therapeutic agents in malignancy.
This study described the administration of one of these agents, EB 1089, to cancer patients. Adverse events were limited to dosedependent predictable effects on calcium metabolism, and the drug can be given at doses similar to the doses that we judge, on the basis of animal studies, are needed for anti-tumour activity.
